176 related articles for article (PubMed ID: 28215073)
1. Identification of Highly Specific Diversity-Oriented Synthesis-Derived Inhibitors of Clostridium difficile.
Duvall JR; Bedard L; Naylor-Olsen AM; Manson AL; Bittker JA; Sun W; Fitzgerald ME; He Z; Lee MD; Marie JC; Muncipinto G; Rush D; Xu D; Xu H; Zhang M; Earl AM; Palmer MA; Foley MA; Vacca JP; Scherer CA
ACS Infect Dis; 2017 May; 3(5):349-359. PubMed ID: 28215073
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
Locher HH; Seiler P; Chen X; Schroeder S; Pfaff P; Enderlin M; Klenk A; Fournier E; Hubschwerlen C; Ritz D; Kelly CP; Keck W
Antimicrob Agents Chemother; 2014; 58(2):892-900. PubMed ID: 24277020
[TBL] [Abstract][Full Text] [Related]
3. MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile.
Butler MM; Shinabarger DL; Citron DM; Kelly CP; Dvoskin S; Wright GE; Feng H; Tzipori S; Bowlin TL
Antimicrob Agents Chemother; 2012 Sep; 56(9):4786-92. PubMed ID: 22733075
[TBL] [Abstract][Full Text] [Related]
4. A high-throughput small-molecule screen to identify a novel chemical inhibitor of Clostridium difficile.
Katzianer DS; Yano T; Rubin H; Zhu J
Int J Antimicrob Agents; 2014 Jul; 44(1):69-73. PubMed ID: 24837414
[TBL] [Abstract][Full Text] [Related]
5. The Clostridium difficile proline racemase is not essential for early logarithmic growth and infection.
Wu X; Hurdle JG
Can J Microbiol; 2014 Apr; 60(4):251-4. PubMed ID: 24693984
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.
Kumar M; Mathur T; Barman TK; Ramkumar G; Bhati A; Shukla G; Kalia V; Pandya M; Raj VS; Upadhyay DJ; Vaishnavi C; Chakrabarti A; Das B; Bhatnagar PK
Antimicrob Agents Chemother; 2012 Nov; 56(11):5986-9. PubMed ID: 22869573
[TBL] [Abstract][Full Text] [Related]
7. In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy.
Carman RJ; Boone JH; Grover H; Wickham KN; Chen L
Antimicrob Agents Chemother; 2012 Nov; 56(11):6019-20. PubMed ID: 22908175
[TBL] [Abstract][Full Text] [Related]
8. Comparison of resistance against erythromycin and moxifloxacin, presence of binary toxin gene and PCR ribotypes in Clostridium difficile isolates from 1990 and 2008.
Ilchmann C; Zaiss NH; Speicher A; Christner M; Ackermann G; Rohde H
Eur J Clin Microbiol Infect Dis; 2010 Dec; 29(12):1571-3. PubMed ID: 20632051
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.
Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
Antimicrob Agents Chemother; 2012 May; 56(5):2493-503. PubMed ID: 22290948
[TBL] [Abstract][Full Text] [Related]
10. In vivo selection of moxifloxacin-resistant Clostridium difficile.
Mena A; Riera E; López-Causapé C; Weber I; Pérez JL; Oliver A
Antimicrob Agents Chemother; 2012 May; 56(5):2788-9. PubMed ID: 22371889
[No Abstract] [Full Text] [Related]
11. Surface layer protein A variant of Clostridium difficile PCR-ribotype 027.
Spigaglia P; Barbanti F; Mastrantonio P
Emerg Infect Dis; 2011 Feb; 17(2):317-9. PubMed ID: 21291621
[No Abstract] [Full Text] [Related]
12. Improving the reproducibility of the NAP1/B1/027 epidemic strain R20291 in the hamster model of infection.
Kelly ML; Ng YK; Cartman ST; Collery MM; Cockayne A; Minton NP
Anaerobe; 2016 Jun; 39():51-3. PubMed ID: 26946361
[TBL] [Abstract][Full Text] [Related]
13. Fluoroquinolone resistance and Clostridium difficile, Germany.
Zaiss NH; Witte W; Nübel U
Emerg Infect Dis; 2010 Apr; 16(4):675-7. PubMed ID: 20350385
[TBL] [Abstract][Full Text] [Related]
14. Increased sporulation rate of epidemic Clostridium difficile Type 027/NAP1.
Akerlund T; Persson I; Unemo M; Norén T; Svenungsson B; Wullt M; Burman LG
J Clin Microbiol; 2008 Apr; 46(4):1530-3. PubMed ID: 18287318
[TBL] [Abstract][Full Text] [Related]
15. Multidisciplinary analysis of a nontoxigenic Clostridium difficile strain with stable resistance to metronidazole.
Moura I; Monot M; Tani C; Spigaglia P; Barbanti F; Norais N; Dupuy B; Bouza E; Mastrantonio P
Antimicrob Agents Chemother; 2014 Aug; 58(8):4957-60. PubMed ID: 24913157
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.
Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
Antimicrob Agents Chemother; 2012 Mar; 56(3):1613-5. PubMed ID: 22183166
[TBL] [Abstract][Full Text] [Related]
17. The insect peptide coprisin prevents Clostridium difficile-mediated acute inflammation and mucosal damage through selective antimicrobial activity.
Kang JK; Hwang JS; Nam HJ; Ahn KJ; Seok H; Kim SK; Yun EY; Pothoulakis C; Lamont JT; Kim H
Antimicrob Agents Chemother; 2011 Oct; 55(10):4850-7. PubMed ID: 21807975
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571.
Leeds JA; Sachdeva M; Mullin S; Dzink-Fox J; Lamarche MJ
Antimicrob Agents Chemother; 2012 Aug; 56(8):4463-5. PubMed ID: 22644023
[TBL] [Abstract][Full Text] [Related]
19. A novel agent effective against Clostridium difficile infection.
Dvoskin S; Xu WC; Brown NC; Yanachkov IB; Yanachkova M; Wright GE
Antimicrob Agents Chemother; 2012 Mar; 56(3):1624-6. PubMed ID: 22203600
[TBL] [Abstract][Full Text] [Related]
20. Elevated levels of intestinal inflammation in Clostridium difficile infection associated with fluoroquinolone-resistant C. difficile.
Pawlowski SW; Archbald-Pannone L; Carman RJ; Alcantara-Warren C; Lyerly D; Genheimer CW; Gerding DN; Guerrant RL
J Hosp Infect; 2009 Oct; 73(2):185-7. PubMed ID: 19709778
[No Abstract] [Full Text] [Related]
[Next] [New Search]
